Effects of DynaMatrix® on angiogenic cytokine expression from human dental pulp fibroblasts : an in vitro study by Adams, Joseph Benjamin
  
  
 
 
EFFECTS OF DYNAMATRIX® ON ANGIOGENIC CYTOKINE EXPRESSION 
FROM HUMAN DENTAL PULP FIBROBLASTS: 
AN IN VITRO STUDY 
 
 
 
by 
Joseph Benjamin Adams  
 
 
 
 
 
 
Submitted to the Graduate Faculty of the School of Dentistry in partial fulfillment of the 
requirements for the degree of Master of Science in Dentistry, Indiana University School 
of Dentistry, April 2015. 
ii 
 
 
 Thesis accepted by the faculty of the Department of Endodontics, Indiana 
University School of Dentistry, in partial fulfillment of the requirements for the degree of 
Master of Science in Dentistry. 
 
 
 
 
L. Jack Windsor 
 
 
 
 
 
 
Ygal Erhlich 
 
 
 
 
 
Josef Bringas  
 
 
 
 
 
 
Ned Warner  
 
 
 
 
 
 
Susan L. Zunt  
 
 
 
 
 
 
Kenneth J. Spolnik  
Chairman of the Research Committee 
and Program Director 
 
 
 
 
 
 
Date 
                  
  
iii 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS 
 
  
iv 
 
 
 
 
 
I would like to dedicate this thesis to my absolutely amazing wife, Brooke.  I am 
so blessed to have known you for 12 years! Where has the time gone? Thank you for 
always being there, particularly in the difficult times with loving support and 
encouragement. I am so thankful that God brought us together to enjoy life.  Although we 
have celebrated many momentous achievements – graduations from high school, college, 
and professional training, and our wedding – nothing compares to the birth of our son, 
Rafe Benjamin!  To watch you be a mom brings me so much joy!  Rafe is unbelievably 
blessed to have you as his mother. I am so excited to see what God has in store for our 
new family.  I love you and Rafe more than words could ever describe. 
Mom and Dad, you raised me in a loving, caring and joyful home that helped to 
shape me into the man that I am today. You are both such great examples of what it 
means to live for Christ! You instilled principles such as hard work, determination, and 
perseverance, which I have lived by every day. Your service to others in your careers and 
through global missions is inspiring.  You lead by example and I respect you for that.  I 
love you both very much.  
Dr. Spolnik, you have been a mentor, an example in faith, and a friend since the 
beginning of my pursuit of dentistry.  I admire your work ethic and dedication to the 
department, as well as in life.  As the leader of the department, you set the tone.  It is a 
positive, uplifting tone that promotes learning, respect for others and professional growth 
all while incorporating the right amount of fun.  Thank you for all the advice, 
encouragement, and friendship.   
v 
 
 
Dr. Ehrlich, I really appreciate your help and guidance with the research and 
writing of my proposal and thesis.  However, I am most thankful for our non-endo-related 
conversations. They were interesting, thought-provoking, and enjoyable. Also, I will 
never forget our trip with Avni and Scott to the Ohio State meeting; it was a very fun 
road trip.  
Dr. Windsor, this thesis would not have been possible without your knowledge 
and expertise, and the use of your lab.  Thank you for your guidance, encouragement and 
generosity.  You and Jun were a tremendous help in the completion of the study. Thank 
you!    
Dr. Vail, you are one of the kindest people I have ever met. It was a privilege to 
have you as a full-time faculty, even for a semester.  Thanks for coming in Tuesday 
mornings after you went to private practice.  We had fun and learned a lot.  
 Dr. Bringas, I appreciate your attention to detail and meticulousness. It is 
inspiring. I really enjoyed our non-endo talks, particularly the golf talk. It was a pleasure 
to have you as an instructor, thank you. 
Dr. Legan, your endodontics career is remarkable. It is very encouraging to see 
your passion for endodontics and teaching others. Thanks for being a great example.   
Dr. Warner, I had a great time working with you in the undergrad endo clinic and 
in the pre-doc lab. You were a joy to be around. Thank you for all the encouragement to 
conduct my research and to write this thesis. It was great to have your perspective on 
private practice as well. Thanks for being Dr. NO when I did not want to fill that role. 
Dr. Adams (Uncle Bill), thank you for encouraging me to pursue dentistry as a 
career, in particular endodontics. It was always a pleasure to work with you on Fridays.  
vi 
 
 
Your faith is clearly displayed through your kindness and willingness to serve others.  
Thank you for all the encouragement, support, and guidance.   
Dr. Deardorf, I will miss our endodontic confessions on Wednesdays. I learned a 
lot in your class. On a side note, I will never forget the silly string case. Thank you for 
being so dedicated to teaching us. 
Dr. Hine, it has been great getting to know you better over the last two years.  
Clinic always ran smoothly when you were the attending doctor because of your cool, 
laid-back personality. We did some difficult cases together, and I really enjoyed learning 
from you. It was fun talking about sports, practice management, and life in general.  
Thanks for coming in. 
Dr. Sahni, I love your excitement for endo! It’s contagious. You set the bar. I 
hope to reach it someday. Thanks for pushing me to better myself.   
Dr. Berman, I really appreciate you for taking the time to teach us in clinic. You 
are very courteous and kind. I enjoyed our conversations and time together. Thank you. 
Dr. Steffel, you are a wealth of knowledge. It was nice to have a different 
perspective and philosophy, yet still achieving the same goals. Our conversations, 
although not always about endo, were entertaining and thought-provoking. Thanks for 
sharing your time and knowledge. 
Dr. Newton, thank you for making the effort to mentor us through the board 
certification process. I believe that your insight and guidance has not only motivated me, 
but will prove invaluable throughout the process of becoming a diplomate. Thank you. 
  
vii 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
  
viii 
 
 
 
 
Introduction……………………………………………………………………… 1 
 
Review of Literature……………………………………………………………... 
 
8 
 
Methods and Materials…………………………………………………………... 
 
27 
 
Results…………………………………………………………………………… 
 
32 
 
Figures…………………………………………………………………………… 
 
34 
 
Discussion……………………………………………………………………….. 
 
47 
 
Summary and Conclusions………………………………………………………. 
 
55 
 
References………………………………………………………………………. 
 
58 
 
Abstract…………………………………………………………………………. 
 
68 
 
Curriculum Vitae                                                                                                           
 
 
 
  
ix 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ILLUSTRATIONS 
  
x 
 
 
 
 
FIGURE 1 
 
Overview of the study design……….................................... 
 
35 
  
FIGURE 2 
 
Image of DyanMatrix® membrane cut into a circle that was 
placed into the wells.………………………………………. 
 
36 
 
FIGURE 3 
 
Six-well plate with three experimental groups in the top three 
wells.....................…………………………………………..  
…………………………………….. 
 
 
37 
 
FIGURE 4 
 
Test tube rack with test tubes containing the supernatant 
collected from each of the three wells……………………… 
 
   
 
 
38 
 
 
 
 
FIGURE 5 
 
Centrifuge used to spin down cells into pellicle during cell 
growth and subculture phase……………………………… 
 
 
39 
 
FIGURE 6 
 
Light microscope used for hemocytometry…………………..  
 
40 
 
FIGURE 7 
 
RayBio® Human Angiogenesis Antibody Array C1 Kit……..                
 
41
  
FIGURE 8 
 
 
FIGURE 9 
 
Schematic illustration of the steps involved in cytokine array 
analysis ……………………………………………................ 
 
Images of autoradiography films from the various samples…. 
 
 
42 
 
43 
 
 
 
 
 
 
TABLE I 
   
RayBio® Human Angiogenesis Antibody Array C1 Map…… 
 
44 
  
TABLE II 
 
TABLE III                    
 
Quantitative data From cytokine array membranes………...... 
 
Mean (SE) for each cytokine and p-values for comparisons.  
Highlights indicated statistically significant differences 
in p-values……………………………………………………. 
 
 
45 
 
 
 
46 
 
 
 
      
     
  
1 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
2 
 
 
 
For generations, the loss of, or severe damage to a body part resulted in the use of 
prostheses or perhaps a transplant of some kind. Materials used for transplants are 
categorized as follows: autograft (derived from the same individual); allograft (derived 
from a different individual of the same species); xenograft (derived from non-human 
sources), or alloplast (derived from synthetic material).
1,2
    
The field of material science is evolving rapidly with technological advancements 
such as three-dimensional bioprinting and even gene regulation/therapy.
3,4
 An increase 
has been observed in the use of more durable synthetic materials (e.g., Teflon, silicone) to 
replace or rebuild diseased tissues of the human body. Despite all advancements, many 
newer materials are physically and functionally different from the original human form, 
and they supply more of a structural rather than a functional replacement of the original 
tissue.
5
        
The demand for original human tissue has created the field of tissue engineering 
from the study of cell biology.
6
 At the turn of the century, this was considered a novel 
approach and is still being explored. Tissue engineering is the field of functional 
restoration of tissue structure and physiology for impaired or damaged tissues because of 
cancer, disease, or trauma.
7
 Tissue engineering relies on living cells in various ways to 
maintain, enhance, or restore tissues and organs.
8 
In the process, such engineering utilizes 
and integrates principles from various other fields such as cell transplantation, material 
science, and engineering.
5
 An outgrowth of the increased knowledge in the field of tissue 
engineering has been the development of a scientific discipline termed “regenerative 
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medicine.”6 Regenerative therapy involves the combined interplay of three key elements: 
stem cells, some type of scaffold, and cytokines.
6
 Regenerative therapies have become an 
alternate method for restoration of tissues and/or organs instead of autografts, allografts, 
or artificial prostheses.
9 
Tissue engineering and regenerative therapies have shown 
promising results in the field of dentistry. The field of regenerative endodontics aims to 
utilize the principals of tissue engineering to replace the pulp-dentin complex in the 
diseased tooth.
5
    
Regenerative endodontic therapy via revascularization is a form of tissue 
engineering that is being utilized to overcome the challenges that a necrotic immature 
permanent tooth presents. One of the most significant challenges apart from debridement 
of the canal system can be found in conventional obturation. These immature teeth have 
open apices, which dramatically increase the risk of over-extension of material beyond 
the apical foramina. Apexification utilizes calcium hydroxide (traditional approach) or 
more recently, mineral trioxide aggregate, to induce the formation of an apical hard tissue 
barrier that prevents overfill during conventional obturation.
10
 Although these 
developments ease obturation, the tooth remains fragile with compromised periodontal 
support. Consequently the tooth has a less than desirable prognosis due to a high 
susceptibility to fracture.
1
 Modern regenerative endodontic therapy aims to address these 
shortcomings. 
Several studies have shown healing of apical periodontitis, continued 
development of the root apex, and an increase in root canal wall thickness
4
 using 
regenerative endodontic techniques.
11-13
 The American Association of Endodontics 
announced a suggested regenerative endodontic protocol that includes multiple 
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appointments. The canal is irrigated at the first appointment and followed by placement 
of a low concentration of antibiotic paste as an intracanal medicament. The patient is to 
be seen in three to four weeks and anesthetized without a vasoconstrictor. The  
medicament is then rinsed from the canal with 17-percent ethylenediaminetetraacetic acid 
and bleeding is evoked by careful laceration of the apical tissue. Mineral trioxide 
aggregate is then placed over the blood clot and the canal is sealed with a permanent 
coronal restoration.
14
 Thus, the revascularization is accomplished by careful laceration of 
the apical papilla with an endodontic file to encourage hemorrhage into the empty 
disinfected canal space. The end result of revascularization promotes growth of vital 
pulp-like tissue into the disinfected canal space and continued root formation both in 
length and width.
11,15 
The clot formed serves as a scaffold that supports mesenchymal 
stem cells and residential cells, including pulp fibroblasts, and provides nutrients and 
multiple growth factors, which are required for cell differentiation and dentin/root 
formation. 
16 
Variations in the level of induced blood flow affect the quality of the blood clot, 
and the amount and quality of continued root development.
12, 17
 Case reports have 
suggested that platelet-rich plasma can be used as a successful scaffold material.
18
 
However, scientists are still searching for materials that can serve as better scaffolds than 
the induced blood clot.
19, 20
 The research on scaffold materials evolved out of early 
unsuccessful experiments from Nygaard Ostby and the role of blood clots in attempts at 
regeneration. 
13
 Regenerative endodontic therapy was initiated in the early 21
st
 century.  
From the early 21
st
 century until now, about 60 studies related to regenerative procedures 
have been conducted.
21
 There are several variations in the clinical protocol for 
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regenerative endodontic therapy in more recent studies.
21
 Despite all the technological 
advancements made in tissue engineering, a protocol is still needed that yields consistent 
results of pulp tissue regeneration inside a tooth.
21
  
It is believed that an exogenous scaffold may be more predictable for pulp tissue 
regeneration and continued root formation than simply a blood clot. An ideal scaffold 
would facilitate cell organization, proliferation, differentiation, and vascularization 
essential for the success of pulpal regeneration.
14
 DynaMatrix® is a natural membrane 
scaffold made of the porcine small intestine after decellularization and sterilization. It 
preserves the natural three-dimensional organization of extracellular matrix (ECM) 
molecules, especially Type I collagen, and contains functional proteins such as growth 
factors and cytokines.
22,23 
Growth factors are any group of proteins that stimulate the 
growth of specific tissues, while cytokines are defined as any group of small, short-lived 
proteins that are released by one cell to regulate the function of another cell, thereby 
serving as intercellular chemical messengers.
24
 The chief difference is that growth factor 
implies a positive effect on cell division, while cytokines are considered neutral with 
respect to cell proliferation. Cytokines can have positive effects (like growth factors) or 
negative effects. All growth factors are cytokines, yet not all cytokines are growth 
factors. Specifically, this study will measure the angiogenic growth factors/cytokines 
listed in Table I. DynaMatrix® is used as a scaffold in other areas of medical and oral 
surgery to promote wound healing and tissue regeneration.
23 
Its application in 
endodontics is limited to assist with wound healing of periapical and periradicular 
surgeries. It should be noted that other growth factors such as dexamethasone and dental 
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proteins have been shown to stimulate dental pulp cells to differentiate into cells 
resembling odontoblasts/osteoblasts, adipocytes, or chondrocytes.
25 
The aim of this in-vitro study was to determine if human dental pulp fibroblasts 
(HDPFs) seeded on DynaMatrix® membrane would alter their production of angiogenic 
cytokines. 
Previously, a study on DynaMatrix® membrane and dental pulp stem cells 
reported significant differences in angiogenic cytokine expression (Baker, unpublished 
data). HDPFs are the most numerous cells in the dental pulp
26  
helping to form and to 
maintain the extracellular matrix through the production of collagen. They also have 
immunological properties and express many important cytokines.
15
 These attributes could 
make the HDPFs more clinically relevant in advancing the protocol for regenerative 
endodontic therapy.  Angiogenesis cytokine arrays have been established as a viable 
method for assessing the expression of angiogenic cytokine factors 
27
 and will be used in 
this study. Therefore, since cytokines can either have a negative or positive effect on 
cells, the hypothesis was to see if HDPFs seeded on DynaMatrix® membranes would 
alter the production of cytokines. Such production would be more successful if the 
porcine growth factors/cytokines from the Dynamatrix membrane would positively affect 
the HDPFs to secrete angiogenic cytokines and ultimately stimulate regeneration.  
 
CLINICAL SIGNIFICANCE         
 DynaMatrix® scaffolds have been used successfully in dentistry and medicine. 
Their ability to support fibroblast activity will make them potential scaffolds for 
regenerative endodontics.                                                                    
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HYPOTHESES                                                                                                       
Null: There will be no significant alterations in angiogenic cytokine expression 
when HDPFs are seeded on the DynaMatrix® membrane when compared with the 
membrane or cells alone. 
Alternative:  HDPFs seeded on the DynaMatrix® membrane will alter the 
expression of angiogenic cytokines when compared with the membrane or cells alone. 
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HISTORY OF ENDODONTICS 
Although some authors have cited accomplishments made in endodontics from 
ancient times, the most remarkable advancements became much more frequent in the 17
th
 
century. The first dental book written in English was published by Charles Allen in 
1687.
28
 He described removing an infected tooth as “taking out the rotten teeth or stumps 
and putting in their places some sound ones drawn immediately out of some poor body’s 
head.”29 The idea of replacing an infected tooth with something else, such as another 
person’s tooth, as Allen suggested, has proved to be a challenging task. The study of 
dentistry and endodontics has been an ever-changing process. 
A fine piece of work, The Surgeon Dentist, was written by Pierre Fauchard in 
1728.  Fauchard, who is regarded as “the father of modern dentistry,” accurately 
described root canal systems and pulp cavities of various teeth.
28
 In even more detail, the 
book also described the practice of relieving abscesses and draining pus by drilling access 
holes in teeth.  After these teeth were left open to drain for a few months, the pulp 
chamber was filled with lead foil.
28
 Fauchard was a resourceful man and described the 
placement of cinnamon or the oil of cloves to the affected area of deep caries for 
treatment. In addition to drainage procedures, Fauchard described a pulp extirpation 
procedure using a small pin.
28
  
Phillip Pfaff was a German dentist who cited a pulp-capping procedure in 1756, 
which involved cutting a piece of gold or lead to fit approximately the shape of the 
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opening over the pulp tissue. The metal was concavely shaped in a way to avoid direct 
contact with the pulp.
28
     
King Louis XV of France had a personal dentist. The dentist Bourdet described in 
1757 a process of extracting carious teeth, filling the root canals with gold or lead, and 
then replanting them, similar to the extract replant procedure used today. He also 
described a type of treatment involving the dislocation of a symptomatic tooth in order to 
sever the nerve. Then, he would immediately replace the tooth into its socket.
29
 Although 
Bourdet was ahead of his time, he was not the first to treat symptomatic teeth in this 
manner. The same procedure had been described in the 11
th
 century A.D. by the Arabian 
physician Avicenna.
30
     
The first endodondic procedures performed in the US have been credited to 
Robert Woofendale.  He was an English practitioner who immigrated to New York in 
1766.  He sought to alleviate dental pain by cauterizing the pulp with a hot instrument, 
followed by the placement of cotton pellets into the canals.
31,32
  
By the late 1700s, a manuscript appeared on diagnosing dental disease written by 
a German dentist, Frederick Hirsch. His means for diagnosis were by tapping the 
suspected teeth, and noted that diseased teeth were tender to percussion. He 
recommended perforation of the tooth in the cervical area followed by insertion of a red-
hot probe. The final step in his protocol was to fill the cavity with lead.
33
  
 In the early 19
th
 century, there was a change in thought about infected teeth.  A 
concept emerged regarding the importance of tooth vitality and how it related to pulp 
treatment.  This time period was significant enough to be called, “The Vitalistic Era.”28 In 
1805 J.B. Gariot became one of the first to advance the idea that obliteration of the pulp 
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does not destroy the vitality of the tooth.
34
 In 1809 an Irishman named Edward Hudson 
practicing in Philadelphia built upon Gariot’s theory that a pulpless tooth can remain in 
the mouth and began to place fillings in root canals. Hudson has been given credit for 
being the first dentist to do this. He designed his own instruments, which he used to pack 
gold foil in the canals.
31,35
 Hudson was innovative for his time because he advocated the 
preservation of the natural dentition.
36 
In 1819 John Callow credits Charles Bew with describing the flow of blood into 
the pulp through the apical foramen and out through the dentinal wall and the periodontal 
membrane in his work, Opinions on the Causes and Effects of Diseases in the Teeth and 
Gums.  Bew joined others of his time who subscribed to the vitalistic theory.
34
 Leonard 
Koecker, who wrote Principles of Dental Surgery in 1826, was one of Bew’s 
contemporaries. Koecker’s book was the standard in the field for 50 years.36  Koecker 
said a destroyed pulp could cause the dentinal core of the tooth to die, and that once dead, 
it would present itself as a foreign body, thus necessitating the extraction of the dead 
tooth. To avoid this fate for the tooth, Koecker advocated a pulp-capping procedure 
(essentially the same procedure described by Pfaff in 1756).
34,37,38
   
The “vitalistic” or “double membrane” theory was formulated and presented by 
S.S. Fitch in his book “System of Dental Surgery,” in 1829.  Fitch promoted the notion 
that teeth were like hollow bones with an outer periosteum (periodontal membrane) and 
an inner periosteum that lay between the pulp and the dentin.  Thus Fitch believed that 
the crown was nourished solely by the dental pulp or its membrane, whereas the roots 
were nourished by the pulp membrane on the interior, and by the alveolar membrane on 
the exterior.
28
  Support for this concept led to the practice of removing the crowns of 
12 
 
 
teeth after extirpation of the pulp. The reasoning for this practice was that the source of 
nourishment had been removed to the crown. However, the root was left in the socket, 
because it was believed to receive continued nourishment via the periodontal membrane.  
The root was then restored with a pivot crown.
34, 38
     
 John Hunter, a British surgeon and anatomist, believed that dentin possessed none 
of the properties of living tissue and was devoid of circulation, sensibility, and capability 
of repair. He was a proud supporter of an opposing philosophical position that advocated 
a “nonvitalistic” theory.28  Hunter was not alone in his belief in the nonvitalistic theory; 
Cuvier and Robertson, also British, supported the nonvitalistic theory.
34
  
 In 1836 a drastic change in the approach to vital pulp extirpations was when 
Shearjashub Spooner of New York used a protoplasmic poison (arsenic trioxide) to 
devitalize the pulp before removing it.
31
 Although this was a new approach in modern 
Western medicine, this procedure was actually invented by the ancient Chinese. In 
ancient Chinese medicine, the treatment for jaw abscesses was placement of arsenic 
trioxide.
30
  Such treatment rapidly grew in popularity due to its success in eliminating the 
pain involved in the removal of vital pulps. Unfortunately, this also led to overuse of 
arsenic for devitalization of pulps and for treatment of teeth with dentin hypersensitivity.  
Arsenic was still being used by many dentists as recently as the 1920s to destroy the pulp 
before removing it.
39
     
One year later in 1837, a father and son, Jacob and Joseph Linderer, advocated 
using essential oil as a pulpal obtundant before restoring a tooth with an exposed pulp.
40
 
The first root canal broach was invented by Edwin Maynard in 1838. He created it by 
filing a watch spring. Maynard also designed hoe-like instruments for shaping and 
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enlarging root canals.
41
 In 1839 Baker described a treatment for an exposed nerve that 
included removal of the nerve, followed by cleaning of the canal and then filling it with 
gold foil. It is in fact Baker who has been credited with writing the first published 
account of pulpal extirpation, root canal cleaning, and filling.
28,30
   
Throughout the decade of the 1850s, variations in root canal filling material were 
experimented with, including plugs of wood soaked in creosote.
28
 In an attempt to create 
a seal with the wooden plug filling material, a liquid cement was used. This particular 
sealer contained gutta-percha, quick-lime, powdered glass, feldspar, and metal filings.  
This mixture was also used as a temporary restoration material.
39
  
At a meeting of the Odontological Society of London in 1857, a man by the name 
of Thomas Rogers presented a series of 220 pulp-capping cases, 202 of which were 
considered successful. Rogers listed and described conditions that would lead to the 
success of a pulp-capping procedure including: general good health of the patient; 
freedom from inflammatory tendencies; absence of previous considerable pain from the 
affected tooth; absence of disease in other parts of the tooth, and no caustics to decrease 
the pain. Rogers’ overall assessment and treatment recommendations proved to be 
accurate through modern times with the exception of his final protocol recommendation 
in the case of pulp-capping failure: three leeches and a laxative.
28 
Major innovations in endodontic treatment were seen at the close of the 19
th
 
century, when techniques began to look more like the modern techniques. Advancements 
in asepsis were brought about by S.C. Barnum of New York, who introduced the use of 
the rubber dam to isolate the tooth during the placement of gold foil restorations in 1864.  
It was quickly adopted for use in endodontic procedures to provide a more aseptic 
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environment for treatment.
30,31
 In 1867 G.A. Bowman of Missouri was given credit for 
being the first to only use gutta-percha for filling root canals.
31,35,42
     
A big year in endodontic advancements was 1867. Not only did gutta-percha 
make its entry, Magitot suggested using an electric current for pulp testing, and the 
German team of Leber and Rottenstein proved the existence of a parasite they called 
Leptothrix buccalis, which they found to exist on tooth surfaces, carious lesions, and 
within dentinal tubules.
37
 This information led to a better understanding that tooth decay 
could cause gangrene (necrosis) of the pulp, and soon attempts were being made to apply 
Lister’s principles of antiseptic treatment to the realm of pulp treatment.28,40 Also in 1867 
Joseph Lister described using carbolic acid as an antiseptic for surgical procedures. 
 By the late 1870s, the theory of vitalism was challenged by the septic theory. The 
septic theory asserted that pathogenic organisms were the most common cause of 
diseases of the pulp. This theory was promoted by G.O. Rogers in 1878 and Charles S. 
Tomes in 1879.
34
  In 1882 Arthur Underwood expanded the septic theory by suggesting 
that if pathogens could be successfully excluded from the pulp space through the use of 
powerful antiseptic agents, suppuration of the pulp and resultant alveolar abscesses could 
be prevented.
28
 This idea provided new justification for pulp therapy procedures that 
included caustic germicides for bacterial elimination, a practice that remained in vogue 
for more than 30 years.
34
     
Dr. Bowman of Missouri introduced a solution of chloroform and gutta-percha, in 
1895 naming it chloropercha. It was believed to have a superior seal as compared with 
gutta-percha alone. This technique rapidly became widely accepted. One of its chief 
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advocates was M.L. Rhein of New York, who further developed and described the 
technique several years later.
31
        
One of the all time greatest inventors, Thomas Alva Edison discovered that 
calcium tungstate could be used to fabricate fluorescent dental mirrors in 1898. These 
dental mirrors aided in observing pathologic conditions and endodontic results.  
However, the instrument exposed clinicians and patients to excessive amounts of 
radiation, an appreciation of which finally led to their decline in the 1930’s.36   
 Before 1905 cocaine was the anesthetic agent of choice for 20 years, yet things 
changed when Einhorn developed procaine (Novocaine®). This provided an alternative 
to the previously used cocaine that required a limited dosage due to its high toxicity.  
Though the invention of procaine represented a promising breakthrough in dental pain 
control, its wide use for mucosal injections was stifled initially by an inefficient protocol 
that required dissolving the tablet in solution, followed by boiling, cooling, and aspiration 
into a syringe. It would take another 25 years for more accessible block anesthesia 
techniques to be perfected.
39,41,43
     
In 1908 Dr. Meyer L. Rhein, a physician-dentist from New York, developed a 
technique for determining canal length and degree of obturation that utilized a diagnostic 
wire in conjunction with radiographs.
31,37 
Similarly, G.V. Black proposed measurement 
control to determine the length of the canal and the size of the apical foramen in an 
attempt to avoid overfilling.
28
    
The beginning of the 20
th
 century saw the birth of the Focal Theory of Infection 
(or Theory of Focal Infection) that postulates a myriad of diseases are caused by 
microorganisms (bacteria, fungi and viruses) that arise endogenously from a focus of 
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infection.”44 Hippocrates has been credited with perhaps the first report of focal infection 
by attributing the cure of a case of arthritis to a tooth extraction.
45
 The theory experienced 
a resurgence due in part to E.C. Rosenow, a protégé of Frank Billings, who was a famous 
supporter of this theory.
44
 Billings showed in 1909 that streptococci were present in many 
diseased organs, and that these bacteria were capable of traveling in the bloodstream to 
establish a separate infection at a distant site.
43
  
One of the most famous supporters of the theory of focal infection was William 
Hunter, a British pathologist. In October of 1910, Hunter fanned the flame and propelled 
the theory to a state of widespread acceptance,
28 
when he lectured on the topic at McGill 
University in Montreal. The presentation, entitled “The Role of Sepsis and Antisepsis in 
Medicine,” was published in 1911 in the Lancet.28      
The widespread popularity of the focal infection theory led to increased scrutiny 
of endodontic procedures. These times were dark days in the history of endodontics.  
Many physicians and dentists began to recommend extraction of all endodontically 
treated teeth, and this group of advocates was known as the “100 percenters.” Others 
recommended removal of all non-vital teeth, and yet others even suggested that all teeth, 
whether diseased or not, be removed for the sake of prevention, as well as treatment, or 
“therapeutic edentulation” or “the clean-sweep.”44,46    
It was not until around 1930 before a more conservative approach gained 
popularity. Thus, the philosophy of the 100 percenters was the most influential approach 
in dentistry for nearly two decades.
28
 The change in the dominant school of thought was 
driven by reexamining definitive diagnosis, aseptic techniques, bacteriological culturing, 
and improved radiographic practices in conjunction with root canal therapy.
47
 The change 
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was not immediate however, as it would take close to a decade before the more 
conservative approach to the treatment of dental disease would become the standard.
28
 
 Several advancements in 1937 led to a new era, known as the “the scientific 
era.”28 Two landmark discoveries were made in 1937, Logan showed that bacteria can be 
present in normal tissues without having a pathological effect,
32
 and Tunnicliff and 
Hammond found that microorganisms could be found in the pulps of extracted teeth 
“without any evidence of inflammatory tissue changes.”28,43 While there were new 
discoveries, reports also blatently contradicted the focal infection theory. Cecil of Cornell 
Medical College reported 200 cases in which arthritis had been treated by the removal of 
suspected foci with little evidence of positive effects. This led Burket to the conclusion 
that any improvement subsequent to the removal of the microbial center was more likely 
the result of an associative relationship
28
 between the foci and the disease rather than a 
causative one.
48
 These crucial discoveries finally brought an end to the formerly 
widespread practice of wholesale extraction of distressed or non-vital teeth.
28
   
 After the theory of focal infection slowly began to fade, the early 1940s saw a re-
focusing on disinfection. Fred Adams and Louis Grossman promoted the idea of utilizing 
antibiotics as a supplement to root canal therapy. Adams reported used sulfanilamide, an 
antibiotic to treat periapical infections. He was also credited as the first to use penicillin 
in pulp canal therapy.
28,43
 Grossman urged the use of a non-aqueous formulation of 
penicillin for use in endodontics. His recommendation was based on the fact that the 
stability of the compound decreased in cost compared with the conventional manner.  
Later, Dr. Grossman even used penicillin-laced paper points to disinfect root canals.
35
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With all the advancements in endodontics for centuries, there was still not a 
dedicated specialty or organized group of endodontists. However, this changed in 1943 
when the American Association of Endodontists (AAE) was formed in Chicago, 
Illinois.
49
 By 1949 the AAE investigated the possibility of establishing a specialty board 
in endodontics, and by 1956, this idea became a reality with the formation of the 
American Board of Endodontics.
50
 Finally, due to a remarkable development and growth 
of endodontics during the previous 25 years and the tireless efforts of AAE leaders,
49
 the 
American Dental Association recognized endodontics as a specialty in 1963. The first 
examination and certification of Diplomates occurred two years later in 1965.
28,49
 The 
AAE currently boasts roughly 7000 members. and approximately a quarter of those 
members are board-certified.
51 
 
THEORY OF ENDODONTICS 
Arguably the most foundational study in the advancement of modern endodontics 
was conducted in 1965 by Kakehashi, Stanley, and Fitzgerald.
52
 The experiment showed 
that pulps of germ-free rats, when exposed and left open to food impaction, remained 
vital despite the trauma.
52
 This highlighted the role that microbes play in endodontic 
infections and the supreme importance of reducing bacterial loads in order to achieve 
success following endodontic therapy.
53-55
 Failure to achieve this goal can result in apical 
or periradicular periodontitis, which is defined as inflammation and destruction of the 
periodontium that may or may not produce symptoms.
56
    
The ultimate goal of root canal therapy for both primary and secondary 
endodontic infections is to obtain maximal reduction in microorganisms and their toxins 
and to eliminate microbial insult to the pulpal and periapical tissues.
53
 A 1955 study by 
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Stewart highlighted three phases of endodontic treatment: chemomechanical preparation, 
microbial control, and obturation of the root canal.
57
 Of these three phases, Stewart 
identified chemomechanical preparation as the most important phase. This was later 
confirmed by Grossman,
58
 who also identified 13 principles of effective root canal 
therapy as follows:  
1. Aseptic technique. 
2. Instruments should remain within the root canal.  
3. Instruments should never be forced apically. 
4. Canal space must be enlarged from its original size. 
5. Root canal system should be continuously irrigated with an antiseptic.   
6. Solutions should remain within the canal space. 
7. Fistulas do not require special treatment. 
8. A negative culture should be obtained before obturation of the root canal. 
9. A hermetic seal of the root canal system should be obtained. 
10. Obturation material should not be irrigating to the periapical tissues. 
11. If an acute alveolar abscess is present, proper drainage must be 
established. 
12. Injections into infectious areas should be avoided. 
13. Apical surgery may be required to promote healing of the pulpless tooth. 
In 1967 Schilder highlighted the importance of chemomechanical preparation of 
the canal to render it as aseptic as possible via instruments and antiseptics. Once there is 
sufficient reduction in microbial load, the next step is a three-dimensional obturation to 
the cementodentinal junction or 0.5 mm to 1 mm from the radiographic apex.
59
 Ford 
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expanded on the principles listed by Schilder,
60 
who cited three reasons that it is 
important to achieve a three-dimensional obturation. First, it leaves less space for 
bacterial colonization; second, it prevents apical contamination; and third, it prevents 
movement of bacteria along the walls of the canal. In addition to these guidelines for 
obturation, Ford also stressed the importance of aseptic technique including the use of 
rubber dam isolation, adequate coronal restoration of root-canal-treated teeth to provide 
another seal, and appropriate recall to monitor healing. 
 
REGENERATIVE ENDODONTICS 
 Regenerative endodontic procedures can be defined as “biologically based 
procedures designed to replace damaged structures including dentin and root structures, 
as well as cells of the pulp-dentin complex.”61 Though the concept of regenerative 
endodontic procedures is not new (Dr. B.W. Hermann reported on the use of Ca(OH)2 in 
a case report involving a vital pulp amputation
62
), it has received increasing attention in 
recent years.
63,64
 The typical clinical scenario in which regenerative endodontic 
procedures have been employed has been in cases of immature infected teeth with 
incompletely developed apices.
61,64,65
 However, some investigators have described the 
potential to apply these principles to a wide array of clinical situations including mature 
teeth with closed apices and eventually to such endeavors as “replacement of periapical 
tissues, periodontal ligaments, gingiva, and even whole teeth.”61    
Some have questioned the value of applying the principles of regenerative 
medicine to endodontics.
61
 It has been stated that the pulp plays no significant role in the 
fully developed tooth in terms of form, functions, or esthetics and therefore replacing it 
with a synthetic material as in conventional root canal treatment is the most practical 
21 
 
 
approach. Murray and colleagues refute these points,
61
 citing the possibility for staining 
of tooth structure by endodontic filling materials and sealers.
66,67
 Others, including 
Andreasen, have also pointed out the potential for decreased fracture resistance of root 
dentin caused by long-term Ca(OH)2 exposure,
68
 that is a part of certain treatment 
protocols for infected immature teeth. Others have proposed applying the principles of 
regenerative procedures to treat root perforations.
63
     
 Though minor variations exist in the precise protocols used in the regenerative 
endodontic procedures that have been reported in the literature, most practitioners have 
followed an approach that includes disinfection via irrigation of the canal space, 
placement of an intracanal medicament (typically Ca(OH)2 or an antibiotic paste), 
induction of bleeding into the canal from the apical tissues, and placement of a coronal 
seal.
64,69
 The induction of bleeding into the canal space is performed in order to provide a 
fibrin scaffold that can be populated by the cells involved in regeneration, as well as to 
provide a source for cytokines that aid in regeneration and repair.
61,64,69
 The scaffold 
provides a biological “three-dimensional microenvironment for cell growth and 
differentiation, promoting cell adhesion, and migration.”70  
 
ANGIOGENESIS          
 Angiogenesis is defined as the formation of new blood vessels from preexisting 
capillaries, which has great importance in pulp regeneration.
71
Vasculogenesis is defined 
as the formation of the primary vascular plexus from preexisting vascular precursor cells 
in the embryo.
72
 However, angiogenesis is the formation of new blood vessels from 
preexisting capillaries
72
 and is responsible for the majority of the blood vessels formed 
22 
 
 
during physiological and pathologic conditions.
73
 Thus, in the present study, the term 
angiogenesis will be used. 
A key component to achieving success in regenerative endodontic procedures 
involves establishing an adequate blood supply to the tissues involved.
61, 64, 67
 The 
establishment of such a blood supply requires the growth of existing vessels to form new 
branches and extensions in the periapical area and into the root canal itself.
69
 This process 
of new blood vessel growth from previously existing blood vessels is termed 
“angiogenesis.”75 Other physiologic processes that involve angiogenesis include wound 
repair, the ovarian/menstrual cycle and embryogenesis.
76 
Angiogenesis is absolutely 
critical to the entire process, as most cells must be less than 1 mm from a blood vessel to 
survive.
77
  
Angiogenesis can be classified into two types: sprouting angiogenesis and 
intussusceptive (or splitting) angiogenesis.
75
 Sprouting angiogenesis has been the most 
extensively studied method of vessel formation in humans, and it involves a complex 
series of interactions between various growth factors and cytokines that govern the 
development of the new vasculature.
78
 Some chemical messengers induce angiogenesis 
(angiogenic), while others play an inhibitory role (angiostatic). The balance between the 
angiogenic and angiostatic factors is crucial, as aberrant angiogenesis can lead to 
“chronic inflammation associated with chronic fibroproliferative disorders as well as 
growth and metastasis of solid tumors.”76 The formation of new blood vessels through 
angiogenesis is mandatory to increase the survival rate of re-transplanted tissues.
71 
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CYTOKINES  
 The definition of cytokines are “secreted proteins that regulate important cellular 
responses such as proliferation and differentiation.”79 Several cytokines have been 
identified that play important roles in the process of angiogenesis.  One of the earliest 
steps in the process of angiogenesis involves an increase in the permeability of blood 
vessels in response to the presence of vascular endothelial growth factor (VEGF). This 
leads to extravasation of plasma proteins, which create a temporary scaffold for migrating 
endothelial cells
78
 that are induced to migrate in part by the action of insulin like growth 
factor-1 (IGF-1).
80
 Angiogenin and monocyte chemotactic protein-1 (MCP-1) are growth 
factors that aid the process by increasing new vessel growth.
81-83
 Interleukin-6 and 
interleukin-8 (IL-6, IL-8) have also been shown to play a role in angiogenesis, sometimes 
promoting and sometimes inhibiting angiogenesis depending upon the interplay between 
multiple chemical messengers in the local microenvironment.
84-87
   
Transforming growth factor-beta (TGF-β) is another angiogenesis promoting 
cytokine.
88
 In addition to other tissues, it is found in the dentin matrix. It is anti-
inflammatory, promotes wound healing, and has been used to promote mineralization of 
pulp tissue.
61,89
 Fibroblast growth factor (FGF-2) is secreted from a wide range of cells 
and promotes proliferation of a variety of cell-types. It has been applied in regenerative 
endodontic procedures to increase stem cell numbers.
61,85
 Leptin has been shown to exert 
atherogenic, thrombotic, and angiogenic actions on the vasculature.
90
 Leptin is one of the 
two most-abundant, circulating adipokines that plays an important role in leading the 
endothelial cells to be proangiogenic.
90
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One family of enzymes that plays critical roles in multiple physiologic processes 
is the matrix metalloproteinase (MMP) family. MMPs aid in the development and 
morphogenesis of connective tissue and also function in the process of wound healing.  
However, when left unchecked, their activity has been implicated in multiple disease 
processes including tumor cell metastasis, atherosclerosis, and arthritis. Another family 
of molecules known as tissue inhibitors of metalloproteinases (TIMPs) play an important 
role in regulating the activity of MMPs.
91
 There are four isotypes of the TIMPs
92
 and 
types 1-3 have been shown to have inhibitory effects on angiogenesis.
92-94
  
 Interferon gamma (IFN-γ) has also been shown to inhibit angiogenesis in vitro.  
It achieves this inhibitory effect, at least in part, by opposing the action of platelet derived 
growth factor (PDGF).
95
 PDGF, specifically heterodimer BB, has been shown to 
modulate endothelial proliferation and angiogenesis.
95
 Another intracellular mediator, 
epithelial neutrophil-activating protein-78 (ENA-78), plays an important role (as its name 
suggests) in acute inflammation by binding to receptors on polymorphonuclear 
leukocytes (PMNs, neutrophils) to “mediate their spatially-localized activation.”97 
However, studies have also demonstrated a strong correlation between higher ENA-78 
levels and increased vascularity of certain tissues.
76, 98 
       
DYNAMATRIX®          
 Dynamatrix® is an extracellular matrix membrane derived from porcine small 
intestine submucosa (SIS). It is marketed to dental practitioners for use in “guided bone 
and guided tissue regeneration procedures.”99 According to information provided by the 
manufacturer (Cook Biotech, Lafayette, Indiana), “SIS is prepared by removing the 
tunica mucosa from the inner intestinal surface, and the serosa and tunica muscularis 
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from the outer intestinal surface. Further during processing with a series of surfactant and 
ionic solutions, the cells and nuclear matter are removed leaving behind a three-
dimensional, acellular, collagen-rich extracellular matrix (ECM). The isolation and 
disinfection process preserves structural and functional bioactive molecules including, 
collagens (I, III, IV, VI) in their natural, three-dimensional states. This provides the 
framework for the infiltration of host cells and lasting strength during the remodeling 
process. Active growth factors such as fibroblast growth factor (FGF-2), connective 
tissue growth factor (CTGF), and transforming growth factor beta (TGF-β) promote 
angiogenesis, participate in vascular repair and development, and stimulate migration and 
proliferation of cells. Glycoproteins and other protein-carbohydrate complexes such as 
fibronectin, proteoglycans, and glycosaminoglycans can be found in the membranes.  
These serve as chemo-attractors, provide cell attachment sites in the extracellular matrix, 
and help to regulate the complex processes of cell migration, proliferation, and 
differentiation. Elastin is present in negligible amounts.”22    
With regards to its physical properties, the average pore size of the material is 
“~17 μm, with a range from roughly 10 μm to 50 μm. When the product is re-hydrated, 
the pores may be as large as 50 μm. It is extremely sensitive to the manufacturing 
process. Average thickness of SIS is 0.155 mm in the wet state.  Dry product as provided 
collapses to about 0.100 mm.”      
The manufacturer further provides the following information concerning the 
safety of the product:  “All of our devices are composed of porcine small intestinal 
submucosa (SIS).  In order to ensure and maximize patient safety, Cook Biotech utilizes 
only healthy pigs raised at qualified and monitored producers and rendered at USDA-
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certified meat packing facilities. All pigs are sourced in the United States. Further, the 
packing facilities must process only pigs, minimizing the potential cross-contamination 
with animal species known to have the potential for carrying transmissible spongiform 
encephalopathy. However, there are no known naturally occurring transmissible 
spongiform encephalopathy in pigs and cross-species transmission is highly unlikely.”99  
The aim of this in-vitro study was to determine if human dental pulp fibroblasts 
(HDPFs) seeded on DynaMatrix® membrane would alter their production of angiogenic 
cytokines. 
 
HYPOTHESES                                                                                                                
Null: There will be no significant alterations in angiogenic cytokine expression 
when HDPFs are seeded on the DynaMatrix® membrane when compared with the 
membrane or cells alone. 
Alternative:  HDPFs are seeded on the DynaMatrix® membrane will alter the 
expression of angiogenic cytokines when compared with the membrane or cells alone. 
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MATERIALS AND METHODS 
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EXPERIMENTAL DESIGN  
 HDPFs were used in this study. Groups were established as follows: (a) Group 1: 
HDPFs seeded in culture media only; (b) Group 2: DynaMatrix® membrane incubated 
alone in the serum-media without any cells, and (c) Experimental group: HDPFs seeded 
on DynaMatrix® membranes. After allowing 24 hours for cell attachment, serum minus 
media was added. Then, after 72 hours of incubation, the conditioned media was 
collected for cytokine analyses. The conditioned media were analyzed for the expression 
of 20 angiogenic cytokines (see Table I) utilizing cytokine arrays. The density of each 
cytokine expressed was measured, averaged, and statistically analyzed by ANOVA to 
determine the statistically significant differences among the groups with regard to the 
expression or presence of specific angiogenic cytokines.  
 
HDPF CULTURES  
 The HDPFs had already been collected from healthy de-identified teeth extracted 
from patients for orthodontic treatment. These cells were then cultured and stored at 
70°C.  Indiana University Purdue University Indianapolis (IUPUI) Institutional Review 
Board (IRB) approval number 1408977286. Briefly, the teeth were transported from the 
clinic to the laboratory in phosphate buffered saline (PBS) solution. The extracted teeth 
were washed, cracked, and the pulp tissue was removed.  The pulp tissue was minced into 
small fragments, placed in cell culture dishes, and grown in cell culture media.  The cells 
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that grew out of the explants were sub-cultured and maintained as cell lines. HDPFs 
between passage 2 and passage 8 were used in the present study.   
 
HDPF Treatment 
 HDPFs were fed and grown in the Dulbecco's Modified Eagle's medium 
(DMEM) cell culture media. Every three to four days, the cells were sub-cultured to 
avoid overcrowding on the plates. Cells were seeded (75,000) per well in 6-well plates.  
These cells were counted using a hemocytometer and a light microscope (Figure 7).  The 
following experimental groups were tested and are shown in Figure 1: 
(a) Group 1: HDPFs only (C), 
(b) Group 2: DynaMatrix® membrane incubated without any cells (M). 
(c) Group 3: HDPFs seeded on DynaMatrix® membranes (C+M). 
Cells were given 24 hours to allow for attachment.  After 24 hours, the serum plus 
media was removed and 2 ml of serum minus media was added to each well of the 6 well 
plates. After 72 hours of incubation at 37
o
C
 
, the conditioned media from the three 
different groups were collected and stored at -70
o
C until analyzed. 
 
Cytokine Arrays  
The conditioned media from the various groups were used to test for the 
expression of multiple angiogenic cytokines. Equal volumes (1 ml) conditioned media 
were used for the cytokine analysis. The angiogenic cytokine profile from the HDPFs 
alone or HDPFs seeded on DynaMatrix® membranes or membrane alone were evaluated 
utilizing RayBio Human Angiogenesis Antibody Array I (Table I, RayBiotech Inc., 
Norcross, GA).
27
  Briefly, the cytokine array membranes were blocked by 1.0-percent 
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serum for 30 minutes at room temperature and then incubated for three hours with 1 ml 
sample from each of the groups; two hours with biotin-conjugated antibodies provided by 
the kit, and then two hours with horseradish peroxidase-conjugated streptavidin.   
Detection agents supplied by the manufacturer were then added to each membrane for 
two minutes.  The cytokines on the membrane were then visualized by autoradiography 
on x-ray film. With two dots for each type of the cytokine on each membrane, a total of 
four to six determinations for each cytokine were used for further semi-quantification.  
The density of the cytokines was measured with the Quantity One 1-D Analysis Software 
(Bio-Rad Laboratories, Des Plaines, IL).  The experiment was repeated three times and 
the averages were calculated. 
 
Statistical Analysis  
Multiple dots for each cytokine on the array membranes were averaged. For each 
array membrane, the densities were adjusted for the background by subtracting the 
average value of the negative controls and then normalized by dividing by the average of 
the positive controls. The data were then converted back to the original scale by 
multiplying by the average of the positive controls for the first array membrane.  Group 
comparisons were performed using one-way analysis of variance (ANOVA) followed by 
pair-wise tests using Fisher’s Protected Least Significant Differences to control the 
overall significance level at 5 percent. Analyses were performed using SAS (SAS 
Institute Inc., Cary, NC). The distribution of the data was examined and a transformation 
of the data (natural logarithm, rank, etc.) was used.  Based on previous studies, the study 
had approximately 80-percent power to detect a three standard deviation difference 
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between groups, assuming two-sided tests each conducted at a 5-percent significance 
level.   
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RESULTS 
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The results of the angiogenic cytokine arrays used in the study groups are 
presented in Table III. Membrane only (group M) was significantly higher than cells only 
(group C) for bFGF (p = 0.0023). Group C was significantly higher than group M for 
ANG (p = 0.0003), GRO (p = 0.0104), IL-6 (p = 0.0104), IL-8 (p = 0.0104), Leptin (p = 
0.0104), MCP-1 (p = 0.0003), THPO (p = 0.0065), TIMP-1 (p = 0.0254), TIMP-2 
(0.0300), and VEGF (p = 0.0308).  Cells+Membrane (group C+M) was significantly 
higher than group C for bFGF (0.0249), GRO (p = 0.0104), IFN-γ (p = 0.0249), IL-6 (p = 
0.0104), IL-8 (p = 0.0104), and Leptin (p = 0.0104). Group C was significantly higher 
than group C+M for ANG (p = 0.0104), MCP-1 (p = 0.0104), and THPO (p = 0.0308). 
Group C+M was significantly higher than group M for ANG (p = 0.0104), GRO (p = 
0.0003), IFN-γ (p = 0.0023), IL-6 (p = 0.0003), IL-8 (p = 0.0003), Leptin (p = 0.0003), 
MCP-1 (p = 0.0104), TIMP-1 (p = 0.0190), TIMP-2 (0.0123), and VEGF (p = 0.0065). 
The groups did not have significantly different p values for EGF (p = 0.2042), 
ENA-78 (p = 0.6242), IGF-1 (p = 0.2817), PDGF-BB (p = 0.1424), PIGF (p = 0.2817), 
RANTES (p = 0.9670), TGF-beta1 (p = 0.6510) and VEGF-D (p = 0.1424). 
A ratio of the cytokine expression levels was calculated and is presented in Table 
II.   The ratios of Group M and Group C+M against the control group, Group C, were 
determined.  Overall, there was an increase in angiogenic cytokines in the significantly 
different cytokines when comparing group M with group C+M ratios over group C.   
Although there were differences in all 20 of the cytokines evaluated, the discussion and 
conclusions will focus only on the significantly different cytokines.  
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FIGURE 1. Experimental design overview. 
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FIGURE 2. DynaMatrix® membrane provided by manufacturer Cook Biotech 
Inc., West Lafayette, IN, and image of the membrane cut into circle 
to fit into one of the 6-well plates. 
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FIGURE 3. Six-well plate with the three experimental groups in all six wells.   
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FIGURE 4. Test tube  rack with test tubes containing the supernatant collected 
from each of the three wells (HDPFs alone, DynaMatrix® alone, 
DynaMatrix® + HDPFs).  The experiment was run three times 
resulting in 9 separate samples.  
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FIGURE 5. Centrifuge used to spin down cells into pellicle during                                                            
cell growth and subculture phases. 
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 FIGURE 6.  Light microscope used for counting cells.  
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FIGURE 7. RayBio® Human Angiogenesis Antibody Array 1 Kit.  Above: closed 
box;  below: open box. 
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FIGURE 8.  Schematic illustration of the steps involved in cytokine array analysis. 
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A        B       C 
FIGURE 9. Images of autoradiography films from the various samples from this 
study.  A: Membrane-only group; B: HDPFs-only group; C: DynaMatrix® 
+ HDPFs group 
 
 
 
 
 
 
 
Cytokine Arrays 
Numeric value for each dot  
44 
 
 
 
TABLE I 
RayBio® Human Angiogenesis Antibody Array 1 Map   
Key to abbreviations: Angiogenin: aka ribonuclease 5, EGF: epithelial growth factor, 
ENA-78: epithelial neutrophil-activating protein 78, bFGF/FGF-2: basic fibroblast 
growth factor, IFN-γ: interferon gamma, IGF-1: insulin-like growth factor 1, IL-6, 8: 
interleukin 6,8, MCP-1: monocyte chemotactic protein-1, PDGF-BB: platelet-derived 
growth factor BB PIGF: Phosphatidylinositol-glycan biosynthesis class F protein, TGF-
β1: transforming growth factor beta 1, TIMP-1, 2: tissue inhibitor of metalloproteinases 
metallopeptidase inhibitor 1, 2, VEGF: vascular endothelial growth factor, VEGF-D: 
vascular endothelial growth factor D, POS: positive control, Neg: negative control. 
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TABLE II 
Cytokine expression levels (Fold difference compared to control) 
cytokine       M/C         CM/C 
ANG 0.25 0.63 
GRO 0.40 1.60 
IFN-γ 0.50 1.71 
IL-6 0.40 1.60 
IL-8 0.40 1.60 
LEPTIN 0.40 1.60 
MCP-1 0.25 0.63 
TIMP-1 0.32 1.05 
TIMP-2 0.33 1.17 
THPO 0.33 0.54 
VEGF 0.35 1.29 
bFGF 3.83 2.67 
 
Key to abbreviations: C: Cell-only group, M: Membrane-only group, C+M: Cell + 
Membrane group.  The highlighted numbers represent significant differences. 
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TABLE III 
 
Mean for each cytokine ± Standard Deviation (s.d.) and p-values for comparisons*  
Cytokine   C ± (s.d.)                M ± (s.d.)    C+M ± (s.d.) C vs. M      C vs. 
      C+M 
    M vs. 
    C+M 
ANG 3.1 ± 0.4x106 -0.02 ± 0.03x106         1.3 ± 0.1x106 0.0003 0.0104 0.0104 
Bfgf 0.1 ± 0.08x106 1.3 ± 0.3x106         0.7 ± 0.2x106 0.0023   0.0249 0.0828 
EGF 0.1 ± 0.4x106 0.06 ± 0.01x106      -0.001 ± 0.07x106 0.1435 0.1137 0.8719 
ENA-78 0.1 ± 0.09x106 .05 ± 0.05 x106     -0.004 ± 0.04 x106 0.7895 0.3663 0.5114 
GRO 6.7 ± 0.7 x106 0.1 ± 0.09 x106        13.9 ± 0.8 x106 0.0104 0.0104 0.0003 
IFN-γ 0.1 ± 0.05 x106 0.003 ± 0.05x106        0.3 ± 0.01 x106 0.0828 0.0249 0.0023 
IGF-1 0.08 ± 0.06x106 -0.04 ± 0.05x106     -0.01 ± 0.01 x106 0.1300 0.3071 0.5472 
IL-6 0.1 ± 0.6 x106 -0.07 ± 0.03x106                         1.4 ± 0.6 x106 0.0104 0.0104 0.0003 
IL-8 7.1 ± 1.0 x106 0.5 ± 0.5 x106        21 ± 0.5 x106 0.0104 0.0104 0.0003 
LEPTIN 0.1 ± 0.04 x106 -0.01 ± 0.02x106          1 ± 0.2 x106 0.0104 0.0104 0.0003 
MCP-1 4.6 ± 0.2 x106 0.01 ± 0.04 x106       3.3 ± 0.4 x106 0.0003 0.0104 0.0104 
PDGF-
BB 0.09 ± 0.06 x106 -0.02 ± 0.05x106  -0.08 ± 0.04 x106 0.2029 0.0593 0.4061 
PIGF 0.07 ± 0.01 x106 -0.019 ± 0.05x106 0.11 ± 0.049 x106 0.3071 0.5472 0.1300 
RANTES 0.44 ± 0.09 x106 0.47 ± 0.1 x106   0.43 ± 0.10 x106 0.9009 0.9009 0.8038 
TGF-ß1 0.49 ± 0.1 x106 0.32 ± 0.2 x106   0.51 ± 0.10 x106 0.4372 1.0000 0.4372 
THPO 0.1 ± 0.02 x106 -0.005± 0.004x106   0.06 ± 0.01 x106 0.0065 0.0308 0.2488 
TIMP-1 9.2 ± 0.8 x106 0.7 ± 0.7 x106     9.2 ± 0.5 x106 0.0254 0.8276 0.0190 
TIMP-2 7.9 ± 0.9 x106 -0.01 ± 0.05x106     8.7 ± 0.9 x106 0.0300 0.5060 0.0123 
VEGF 0.19 ± 0.03 x106 0.01 ± 0.06 x106   0.3 ± 0.08 x106 0.0308 0.2488 0.0065 
VEGF-D 0.1 ± 0.04 x106 0.017 ± 0.04x106 -0.02 ± 0.02 x106 0.2029 0.0593 0.4061 
 
*Highlighted numbers represent statistically significant difference p < 0.05. 
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DISCUSSION 
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Human dental pulp fibroblasts were capable of attaching and growing on 
DynaMatrix® in vitro. This is valuable information for possible future studies involving 
DynaMatrix® .  This attachment characteristic of the membrane makes it a possible 
candidate for future use as an intra-canal scaffold for regenerative endodontic procedures.  
The results of this in-vitro study support the claim of the manufacturer that 
DynaMatrix® contains “biological signals such as growth factors.”99 One of the 
cytokines in the membrane is fibroblast growth factor (FGF-2). The most significant 
increase across all of the cytokines that were evaluated was seen with basic fibroblastic 
growth factor (bFGF or FGF-2).  bFGF was present in statistically significant higher 
levels in the supernatant from the DynaMatrix-only group when compared with the 
HDPFs-only group. The only possible conclusion for the increased bFGF levels in the 
supernatant of the DynaMatrix-only group, given the fact that no cells were present, is 
that the pro-angiogenic cytokine bFGF was released from the membrane itself.  With the 
exception of bFGF, the levels of expression of the statistically significant other cytokines 
were actually higher in the HDPFs-only group as compared with the Dynamatrix-only 
group.       
In addition to increasing the levels of bFGF from the DynaMatrix® into the 
supernatant, DynaMatrix® appears to have had an effect on the expression of vascular 
endothelial growth factor (VEGF) from the HDPFs. When the fold difference as 
compared with the control, or ratios of the two groups containing Dynamatrix-only and 
Dynamatrix® + cells were calculated, the increase in VEGF was significant (see Table 
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III).  This implies that the increased levels of VEGF in the experimental group were not 
due simply to additive effects between the cytokine molecules from the DynaMatrix and 
those from the HDPFs, but rather that DynaMatrix actually had some sort of stimulatory 
effects that resulted in greater VEGF expression from the HDPFs.  As Imada About 
stated, VEGF exerts strong chemotactic effects on human pulp cells in a dose-dependent 
manner.
2
 Thus the increase of the cytokine VEGF would draw more pulp cells, 
endothelial cells, and fibroblasts to the area. Once present, they could begin to form thin 
cords of interconnecting cells, and exhibited elongations and branching to form a network 
of capillary-like structures corresponding to neoangiogensis.
100
    
Another interesting finding was that the level of bFGF decreased from a ratio of 
3.83 Dynamatrix-only as compared with cells only to a level of 2.67 in the experimental 
group (Dynamatrix+HDPFs) as compared with cells only, which is a 30-percent decrease.  
One explanation is that the bFGF supplied by the Dynamatrix® was metabolized by 
HDPFs.  Another explanation is that the bFGF is binding to the cell surface. This is a 
positive discovery as About states “FGF-2 has been shown to enhance pulp cell 
proliferation.”2 This growth factor was expected to play a very important role in the 
current study, because fibroblasts were used. FGF-2 also plays roles in cell proliferation 
and differentiation important for wound healing and angiogenesis.
72
   
The cytokine leptin was found to be significantly higher in the experimental group 
(DynaMatrix + HDPFs) as compared with both the HDPFs and DynaMatrix® groups.  
Leptin has been shown to exert atherogenic, thrombotic, and angiogenic actions on the 
vasculature.
90
 Leptin is one of the two most-abundant, circulating adipokines that plays 
an important role in proangiogenic/proatherogenic factors in endothelial cells.
90
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Adipokines are cytokines that are secreted by adipose tissue. It is interesting to note that 
both in-vivo and in-vitro studies have demonstrated the activation of endothelial receptors 
by leptin, thus leading to capillary tube formation, a prerequisite for angiogenesis.
101
  
Adipokines such as leptin have been found to up-regulate key proangiogenic 
molecules like the gelatinases (MMPs, MMP-2/-9).
90
 Additionally, leptin has been shown 
to up-regulate and act synergistically with the key angiogenic mediators like FGF-2, 
VEGF, and its receptor VEGFR1, stimulating vascular permeability, consequently 
resulting in functional angiogenesis.
90
 This is of particular interest, because in the present 
study bFGF (FGF-2) and VEGF were significantly higher in the experimental group 
(DynaMatrix + HDPFs), which supports the claim that leptins up-regulate other key 
angiogenic cytokines. These findings are conducive for new blood vessel growth. 
A different mechanism appears to have altered TIMP-2 expression. TIMP-2 levels 
were significantly higher in both the HDPFs-only group and the experimental group 
(DynaMatrix + HDPFs) as compared with the DynaMatrix-only group.  The expression 
of TIMP-2 from the HDPFs was actually not statistically different from the experimental 
group (DynaMatrix + HDPFs).  There was no expression of TIMP-2 in the DynaMatrix-
only group, as shown in Table III. Although the HDPFs express TIMP-2, the DynaMatrix 
did not alter this in a negative way.  There are four isotypes of the TIMPs
92
 and TIMPs 1-
3 have been shown to have inhibitory effects on angiogenesis.
92-94
 The increased levels of 
TIMP-2 and THPO, due to the HDPFs, both of which are inhibitors of angiogenesis, were 
not potentiated by the DynaMatrix®. It should be considered that angiogenesis is a 
complex process in a local micro-environment and that addition of other cell types might 
alter the environment. An unpublished study on human dental stem cells described a pro-
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angiogenic environment with decreases in TIMP-1 and TIMP-2 (Baker, unpublished 
data). 
Although the interaction between the HDPFs and DynaMatrix® resulted in some 
anti-angiogenic cytokine profiles, the most important angiogenic cytokines, bFGF and 
VEGF, for vascularization were increased in this study.
2
 For example, bFGF is present in 
DynaMatrix® and appears to promote expression of bFGF from HDPFs or cleavage of 
the membrane releasing more bFGF.  bFGF is secreted from a wide range of cells and 
promotes proliferation of a variety of cell-types. It has been applied in regenerative 
endodontic procedures to increase stem cell numbers, as well as interact with endothelial 
cells to form capillaries.
61,85,100
  
IL-8 levels were found to be significantly higher in HDPFs only group and the 
HDPFs seeded on DynaMatrix® compared with DynaMatrix® only group.  IL-8 has 
been shown to play a role in angiogenesis, sometimes promoting and sometimes 
inhibiting angiogenesis, depending upon the interplay between multiple chemical 
messengers in the local microenvironment.
85-87
 However, IL-8 is also affiliated with 
inflammatory processes and has been shown to even play a “causative role in acute 
inflammation by recruiting and activating neutrophils.”102 A state of inflammation is 
generally considered detrimental to the success of regenerative endodontic procedures, 
especially in the case of teeth that have undergone trauma. In these teeth, damage to the 
predentin and precementum layers can lead to root resorption in the presence of 
inflammation.
103
  
The measured MCP-1 levels were highest in the HDPFs only group, significantly 
lower in the experimental group (DyanMatrix + HDPFs), and still significantly lower in 
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the DynaMatrix® only group. These results exhibit a cytokine profile that would favor 
the goals of endodontic regenerative procedures when HDPFs are used to supplement a 
pro-angiogenic profile that is lacking in the DynaMatrix® membranes. MCP-1 has been 
shown to promote angiogenesis in multiple studies
83, 104-106
;
 
though the exact mechanism 
by which it achieves this is not completely understood.
107
 Furthermore, one study 
demonstrated novel evidence that the mechanism of MCP-1–induced angiogenesis is 
mediated through pathways involving VEGF and the activation of RhoA small G 
protein.
83
 However, like IL-8, MCP-1 has been shown to be an important mediator of 
inflammation,
108
 which may pose an obstacle to regeneration.   
The preceding discussion highlights generalities concerning the roles of specific 
cytokines, but it is important to recognize that the effects of individual cytokines are 
complicated by various factors. In vivo, cytokines may have different effects depending 
upon their target cell types. Their effects can also be dose-dependent. Therefore, the 
findings of an in-vitro study have to be interpreted accordingly. In addition, many of the 
studies involving research into the roles of various cytokines in the process of 
angiogenesis use animal models and focus on tumor angiogenesis in various parts of the 
body other than the jaw.
105,106,109,110
  The findings of these studies may involve important 
differences from the specific clinical situation involved in regenerative endodontic 
procedures.        
One issue that affects the feasibility of regenerative endodontic procedures is the 
degradation or incorporation of the scaffold. The rate at which the scaffold resorbs should 
mimic as closely as possible the rate of tissue formation.
61
 Collagen has been suggested 
as a possible intracanal scaffold for regenerative endodontic procedures.
69
 A recent study 
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involving revascularization of rat teeth found that an injectable Type 1 collagen scaffold 
was replaced after eight weeks by vascularized connective tissue, thereby “confirming its 
biodegradability and potential use as a scaffold for pulp cell engineering.”74 Several 
studies have investigated techniques for treatment of bone defects in a rat model utilized 
SIS membranes.
111,112
 The bone defects in the rat femurs were treated with bone allograft 
seeded with mesenchymal stem cells and growth factors. This was then wrapped with SIS 
that had been seeded with mesenchymal stem cells. The analysis of the SIS membrane 
demonstrated its complete resorption by 9 weeks.
112
 As DynaMatrix® is an SIS 
membrane that contains collagen, it would likely exhibit a similar rate of resorption (8-10 
weeks) as that found in the two previously mentioned studies, which would be 
appropriate for regenerative endodontic procedures.
74
 As discussed above, another 
critical issue influencing the outcomes of regenerative endodontic procedures is the 
elimination of microbes from the root canal space. To this end, most suggested protocols 
recommend copious irrigation with NaOCl followed by placement of an intracanal 
medicament to maximize microbial elimination. Nevertheless, recent research indicates 
that even the most meticulous efforts to eradicate microbes from the root canal system are 
never completely successful.
113,114
 In light of this reality, various authors have 
encouraged the development of a scaffold that contains an antimicrobial component for 
use in regenerative endodontic procedures.
61,64,69
 DynaMatrix® has no documented 
antibiotic effects, so the addition of an antibiotic to the membrane or simultaneous use of 
the membrane with an intracanal antibiotic solution or paste would likely increase its 
appeal for use in regenerative endodontics.  
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Potential research could include a similar study design to the one utilized in this 
investigation, but could substitute different cells that are known to play an important role 
in angiogenesis, such as endothelial cells. Further clinical relevance could be achieved by 
studying the interaction between DynaMatrix® and a mixed population of various cell 
types, rather than a single cell type. The expression of different cytokines could also be 
studied readily as the manufacturer offers custom-made cytokine array membranes that 
can be designed to screen for specific cytokines as requested by the researcher.
115
 
Ensuing animal studies and human in-vivo studies could be expedited by the fact that 
DynaMatrix® already has a long track record of safe clinical use in humans. 
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SUMMARY AND CONCLUSIONS 
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The HDPFs utilized in this study remained viable after being seeded on 
DynaMatrix® in the presence of culture media in vitro.  The null hypothesis was rejected 
as statistically significant differences in the expression of angiogenic cytokines were 
demonstrated between the experimental group (DynaMatrix® + HDPFs) when compared 
with the control groups (HDPFs-only or DynaMatrix-only).  Specifically, bFGF was 
highest in the (DynaMatrix® only group), lower in the experimental group (DynaMatrix 
+ HDPFs), and lowest in the (HDPFs-only group).  In addition, tissue inhibitor of matrix 
metalloproteinases-2 (TIMP-2) and thrombopoietin (THPO) were significantly higher in 
the (HDPFs only group) than in the (DynaMatrix-only group).  The levels of TIMP-2 and 
THPO did not significantly increase in the experimental group (DynaMatrix® + HDPFs).  
Both TIMP-2 and THPO are inhibitors of angiogenesis. Thus the findings support that by 
adding the DynaMatrix® membranes did not increase the anti-angiogenic cytokines 
TIMP-2 and THPO.  Statistically significant differences in the levels of other cytokines 
were detected among the groups, but those particular cytokines were present in such 
small quantities that they were deemed highly unlikely to result in any biological and 
clinical effects.  These cytokines were IL-6, IL-8, IFN-gamma and GRO. 
DynaMatrix® could potentially improve the regenerative endodontic procedure 
by providing a predictable scaffold for cellular and vascular in-growth into the root canal 
system. As shown in this current study, DynaMatrix® supported HDPFs viability.  
Additionally, it may improve angiogenesis by increasing the quantity of pro-angiogenic 
cytokines present in the local microenvironment such as bFGF, VEGF and leptin.  This 
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would be a result of the released cytokines present in DynaMatrix®, as well as possible 
interactions with the cells involved in regeneration that result in greater expression of 
angiogenic cytokines from these cells. Lastly, it may aid endodontic regenerative 
procedures by down-regulating the expression of potential inhibitors of angiogenesis such 
as THPO and TIMP-2.    
Cytokines such as bFGF, ANG, VEGF and leptin promote angiogenesis or will 
stimulate migration and proliferation of cells. The cytokine expression profile from the 
cells seeded on DynaMatrix® suggests that it might be a suitable scaffold for 
regenerative endodontic procedures. It could improve vascularization by increasing 
angiogenic cytokines in the microenvironment of the disinfected root canal space, 
creating capillary networks and support tissue regeneration. 
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EFFECTS OF DYNAMATRIX® ON ANGIOGENIC CYTOKINE EXPRESSION 
FROM HUMAN DENTAL PULP FIBROBLASTS: 
 AN IN VITRO STUDY 
 
 
by 
Joseph Benjamin Adams  
 
Indiana University School of Dentistry 
Indianapolis, IN 
 
 
 
Introduction:  An exogenous scaffold may lead to more predictable pulp tissue 
regeneration and continued root formation in a regenerative endodontic procedure.  
DynaMatrix® is a natural membrane scaffold made of porcine small intestine, currently 
used in periodontal regenerative surgeries.   
Objective: The purpose of this study was to investigate if human dental pulp 
fibroblasts (HDPFs) seeded on DynaMatrix® membrane would result in an increase in 
the expression of angiogenic cytokines. Materials and Methods:  HDPFs (75,000 per 
well) were seeded in 6-well plates. Three groups were tested: Group 1 (C): HDPFs in 
70 
 
 
media only; Group 2 (M): DynaMatrix® (Cook Biotech, Indianapolis, IN) alone in 
media; and Group 3 (C+M): HDPFs seeded on DynaMatrix® membranes. After 72 hours 
of incubation in serum positive, the conditioned media were collected and analyzed for 
the expression of 20 angiogenic cytokines utilizing RayBiotech Inc., arrays per the 
manufacturer’s instruction. The data were analyzed by ANOVA.  
Results:  Group M was significantly higher than C for bFGF (p = 0.0023). C+M 
was significantly higher than M for ANG (p = 0.0104); GRO (p = 0.0003); IFN-γ (p = 
0.0023); IL-6 (p = 0.0003); IL-8 (p = 0.0003); Leptin (p = 0.0003); MCP-1 (p = 0.0104); 
TIMP-1 (p = 0.0190); TIMP-2 (0.0123).  C was significantly higher than C+M for ANG 
(p = 0.0104); MCP-1 (p = 0.0104); and THPO (p = 0.0308). Cytokines such as b-FGF, 
ANG, and leptin promote angiogenesis, and stimulate migration and proliferation of cells. 
 Conclusion: The cytokine expression profile from the cells seeded on 
DynaMatrix® suggests that it might be a suitable scaffold for regenerative endodontic 
procedures. It could improve vascularization by increasing angiogenic cytokines in the 
microenvironment of the treated root canal and supporting tissue regeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CURRICULUM VITAE 
 
 
 
 
 
 
 
 
 
 
 
Joseph Benjamin Adams  
 
 Diploma, Watauga High School, Boone, NC.  
 
May 2008 BS, University of North Carolina at Chapel Hill 
May 2012 DDS, Indiana University School of Dentistry, 
Indianapolis, IN  
 
July 2013 Certificate, General Practice Residency, Roudebush 
Veterans Affairs Medical Center  
 
June 2015 MSD, Endodontics, Indiana University School of 
Dentistry, Indianapolis, IN 
 
Professional Organizations 
 
2008 to present American Dental Association (ADA) 
2012 to present  Association of Endodontics (AAE) 
  
  
 
 
 
 
 
